There was no evidence that the benefit of IFN-α differed depending on duration or dose of treatment, or by gender, age, site of primary tumour, Breslow thickness, disease stage, or presence of clinical nodes, but patients with ulcerated tumours appeared to obtain benefit from IFN-α [26]. The gene discussed is IFNA1; the disease is neoplasm.